Cypomax

Quick links to important sections

Cypomax

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cypomax

Property Description
Active ingredient Cyproheptadine hydrochloride
Form Tablet and Syrup (Oral solution)
Pharmacological class First-generation Antihistamine and Serotonin Antagonist
General purpose Alleviating allergic symptoms and appetite stimulation
Origin Synthetic compound

Cypomax is a brand-name medicinal product whose active ingredient is Cyproheptadine, classified as a potent, synthetic First-generation Antihistamine that also functions as a significant Serotonin Antagonist.


What Type of Medicine is Cypomax and What is its Composition?

This medicine is a synthetic compound belonging to the piperidine chemical family, with the active substance, Cyproheptadine hydrochloride, provided as a single-ingredient formulation. It is administered via the oral route, commonly available as a solid Tablet or as a liquid Syrup for systemic absorption. Cyproheptadine is characterized by its tricyclic benzocycloheptene structure, which contributes to its unique pharmacological profile. This brand positioning typically focuses on the relief of histamine-related allergic discomfort, a clinically recognized indication for this class of medicine.

Understanding Cypomax’s Pharmacological Class and Purpose

Cypomax is defined by its dual mechanism of action: it works by competitively blocking the effects of histamine at H1 receptors and by antagonizing serotonin receptors (5-HT2). The primary function of the Histamine H1 receptor blockade is to mitigate physiological responses, helping to alleviate the general symptoms associated with allergic reactions. The compound has general utility in various allergic conditions. Furthermore, the strong antiserotonergic action of Cyproheptadine is responsible for its secondary physiological effect of appetite stimulation, a distinguishing characteristic of this medicinal agent. This dual functionality is a key differentiating factor from more selective, modern antihistamines.

What side effects are possible with Cypomax?

Cypomax: Possible Side Effects and Safety Information

Cypomax (cyproheptadine) has a safety profile characterized by its central nervous system (CNS) and anticholinergic effects, which are documented in official regulatory labeling.

Adverse Reaction Profile

System-Organ Class Common Adverse Reactions Serious Adverse Reactions (Documented)
CNS Drowsiness, sedation, dizziness, disturbed coordination. Convulsions, hallucinations, confusion, excitation (paradoxical, especially in children).
Anticholinergic/GI Dry mouth, nose, and throat; constipation; epigastric distress; nausea. Urinary retention, jaundice, hepatitis, cholestasis, hepatic failure.
Other Systems Blurred vision, fatigue. Agranulocytosis, leukopenia, hemolytic anemia, anaphylactic shock, hypotension.

Safety Considerations and Restrictions

Serious Reactions: Rare but serious adverse reactions involve the liver (e.g., hepatic failure, cholestasis) and blood (e.g., agranulocytosis, leukopenia). Hypersensitivity reactions, including anaphylactic shock, are also documented.

CNS Depression Risk: Due to the risk of significant sedation and diminished mental alertness, patients are advised against engaging in activities requiring full concentration and motor coordination, such as driving or operating heavy machinery. This risk is increased by co-administration with alcohol or other CNS depressants.

Contraindications and Cautions:

  • Contraindications include use in newborns or premature infants; in patients with narrow-angle glaucoma, stenosing peptic ulcer, symptomatic prostatic hypertrophy, or bladder neck/pyloroduodenal obstruction; and in patients taking MAO inhibitors.
  • Elderly patients are more susceptible to CNS side effects like dizziness, sedation, and hypotension, requiring cautious dosing. Overdosage in young children may result in severe CNS stimulation, depression, and cardiorespiratory arrest.

Regulatory Safety Summary: The official safety profile is centered on managing the pronounced sedative and anticholinergic side effects and adhering to specific contraindications to mitigate the risk of severe hematologic, hepatic, and cardiorespiratory complications, particularly in vulnerable populations.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Cypomax (cyproheptadine) may result in severe manifestations affecting the central nervous system (CNS) and cardiovascular system, as documented in regulatory labeling. The presentation is highly variable, ranging from profound CNS depression (leading to coma and unresponsiveness) to paradoxical CNS stimulation (including agitation, hallucinations, tremor, and seizures) [NIH DailyMed].

Anticholinergic signs are a documented feature of overdose, which may include dry mouth, fixed and dilated pupils, flushing, and urinary retention [NIH DailyMed]. Severe outcomes include respiratory arrest, cardiac arrest, and death, risks that are specifically heightened in infants and young children [NIH DailyMed].

Required Emergency Action

Immediate medical attention is required in all suspected overdose cases. Emergency services (e.g., 911) or a Poison Control center must be contacted immediately if the individual has collapsed, is experiencing trouble breathing, or cannot be awakened [NIH MedlinePlus].

Management is primarily symptomatic and supportive. The prescribing information confirms that no specific antidote is designated for the overall syndrome. Officially described measures include gastric decontamination via activated charcoal or gastric lavage, and vasopressors may be used to manage documented hypotension [NIH DailyMed]. The use of CNS stimulants is contraindicated in this context.

Therapeutic Uses of Cypomax

What Cypomax Treats: Main Uses and Benefits

Cypomax is commonly used in situations involving certain distressing symptoms across several key therapeutic domains.

The medication is relevant in contexts involving perennial and seasonal allergic rhinitis, allergic conjunctivitis, mild, uncomplicated allergic skin issues like urticaria (hives) and angioedema, as well as for appetite stimulation and the preventive management of recurrent vascular headaches. It is applied across domains where additional symptomatic support is needed.

Easing Allergic Discomfort and Hypersensitivity Symptoms

This domain covers the medication’s use for symptomatic relief from various allergic manifestations. The medication provides support that helps ease the symptom load by addressing symptom clusters that may become intense or disruptive, such as pruritus and chronic sneezing. It is considered relevant in the supportive management of severe, acute allergic episodes.

“The goal of symptomatic relief is to support patients during difficult episodes, assisting with maintaining functional stability when symptoms are more noticeable.”

Supporting Appetite and Prophylactic Relief

Cypomax is relevant in contexts marked by involuntary decreased appetite and is commonly employed to help with appetite stimulation, which may assist with the goal of appropriate weight maintenance or gain. Furthermore, it is applied within the therapeutic area of neurology as a supportive measure for the preventive management of recurrent vascular headaches. This may assist with maintaining functional stability during episodes of heightened symptoms.


Quick Fact: Symptom Management for Pruritus and Hives

Cypomax is commonly used across conditions presenting with acute episodes of itching and hives, and is relevant for easing symptoms that interfere with routine activities.

Regulatory References

  1. U.S. National Library of Medicine’s DailyMed

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Cypomax — Official Regulatory Information


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and Pediatric patients aged 2 years and older have established use for labeled conditions.
Populations for whom use is not recommended Nursing Mothers; use is discouraged due to potential serious adverse reactions in the infant.
Populations for whom use is contraindicated Newborn or premature infants, Nursing Mothers, and Debilitated Elderly Patients.
Age-related eligibility rules Contraindicated in children under 2 years of age. Use in older adults (≥ 65) requires cautious selection.
Condition-specific eligibility rules Contraindicated with Angle-Closure Glaucoma, Stenosing Peptic Ulcer, Symptomatic Prostatic Hypertrophy, and Acute Asthmatic Attack.
Pregnancy and lactation eligibility status Pregnancy use is restricted to when clearly needed. Lactation is contraindicated.
Eligibility-related restrictions Use with caution is required for patients with a history of bronchial asthma, hyperthyroidism, hypertension, or where renal or hepatic function is decreased.

Eligibility Classifications (High-Level)

Category Official Regulatory Statement
Eligibility severity classification Contraindicated (Absolute prohibition) and Use with Caution (Conditional restriction) define the primary boundaries.
Regulatory basis Prescribing Information and Summary of Product Characteristics (SmPC).
Eligibility-context constraints Prohibited when administered concurrently with Monoamine Oxidase Inhibitors (MAOIs).

Resulting Eligibility Structure

Official Eligibility Statements:

  • Use is established for adults and children two years of age and older for labeled purposes.
  • The medicine is formally contraindicated in newborns, nursing mothers, and the debilitated elderly.
  • Prohibitions extend to patients with specific comorbidities, including Angle-Closure Glaucoma, Stenosing Peptic Ulcer, and those receiving MAOI therapy.

Connection to the overall eligibility profile (2–4 sentences): The regulatory profile strictly defines eligible populations through absolute prohibitions based on age, physiological status, and specific underlying conditions. Use is restricted to populations meeting the labeled requirements. The official framework also mandates caution for patients with pre-existing cardiovascular, respiratory, or metabolic conditions.

What should I know about interactions with other medicines?

The official regulatory profile for Cypomax (Cyproheptadine) interactions is defined by specific pharmacodynamic restrictions related to its antihistamine and central nervous system (CNS) activities.

Official Interaction Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated. This combination is strictly prohibited because MAOIs are officially documented to prolong and intensify the anticholinergic effects of Cyproheptadine, thereby increasing the potential for adverse outcomes.

Interacting Substance Class Official Documented Effect Regulatory Classification
CNS Depressants & Alcohol Additive CNS depression (e.g., increased sedation, dizziness) Use with Caution
MAO Inhibitors Intensified anticholinergic effects Contraindicated Combination

The use of Cypomax requires caution when co-administered with other CNS Depressants, including hypnotics, sedatives, tranquilizers, other antihistamines, and alcohol. This co-administration results in additive CNS-depressant effects.

The official labeling also includes population-specific cautions tied to interaction risk. Use is generally contraindicated or cautioned against in elderly and debilitated patients and in nursing mothers. This restriction is based on the formally documented higher likelihood of CNS-related adverse effects, such as dizziness and hypotension, in these susceptible groups. No specific timing-based administration rules or documented interactions with food or specific herbal products are noted in the primary regulatory interaction sections.

Mechanism of Action

Cypomax functions by engaging multiple key mechanistic domains, primarily by acting as a blocker (antagonist) at distinct receptor sites to modulate signaling within specific pathways.

Modulating Histamine Pathways

Cypomax's primary action involves acting within domains of amine-mediated signaling by blocking histamine mathbfH1 receptors. This mechanism limits the impact of excessive histamine activity in both peripheral and central pathways, which results in altered signal transmission within the physiological systems where the mathbfH1 receptor is active.

Influencing Serotonin Signaling

The compound also engages mechanisms that influence serotonergic pathways, specifically by exhibiting antagonism at serotonin 5-mathbfHT2 receptors. This interaction alters downstream signaling dynamics within the serotonergic pathways, influencing central regulatory systems like the hypothalamus.

Interference with Cholinergic Systems

A third mechanistic domain involves the drug's activity as an antagonist at muscarinic acetylcholine (mACh) receptors. This interference with the cholinergic system modifies early molecular steps, resulting in an altered physiological effect on involuntary processes such as glandular secretions and smooth muscle activity.

Dosage and Administration Information

How to use Cypomax — Official Administration Guidelines

Official instructions detail the administration of Cypomax (Cyproheptadine) as an orally delivered medication available in 4 mg tablets and a 2 mg/5 mL syrup. Dosing regimens are individualized based on patient size and response, with the daily requirement administered in divided doses, typically two to three times per day, to provide continuous relief.


Official Dosing and Administration

Administration Scope Official Guideline
Route of Administration Oral
Adult Initial Dose 4 mg three times per day
Adult Maximum Dose Should generally not exceed 32 mg daily, or 0.5 mg/kg
Timing in Relation to Meals May be taken with or without food
Missed-Dose Rules Take the dose as soon as remembered, unless it is near the next scheduled time; do not double the dose
Special Procedural Condition The oral solution must be measured using a calibrated device for accurate dosing

Age-Group Administration Rules

For pediatric patients, the maximum daily dose is adjusted based on age group. For children aged 7 to 14 years, the dosage should not exceed 16 mg per day. For younger children aged 2 to 6 years, the maximum dosage is 12 mg per day. Dosing for older adults is suggested to be initiated at the low end of the usual adult range. Elimination is reduced in renal insufficiency, requiring a lower dose and close monitoring as a procedural condition.

Resulting Procedural Structure

The official instructions mandate that the appropriate starting dose is titrated upward according to patient response and size, remaining within the defined maximum daily limits. The schedule requires a divided dose approach throughout the day, and the liquid formulation necessitates a calibrated measuring tool for proper administration. These steps define the standardized use protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials: Efficacy and Outcomes

The body of research surrounding this intervention primarily comes from Phase 3, randomized, double-blind, placebo-controlled clinical trials. The research focused on the drug's activity in modulating the CGRP pathway, which is implicated in the migraine process.

Investigators sought to determine whether the drug influenced the frequency and severity of migraine attacks across various patient demographics.

  • Migraine Frequency: Several trials measured the average number of migraine days per month. The findings generally reported on the comparison of monthly migraine day averages between the drug and placebo groups, with the drug group consistently showing a lower average.
  • Chronic Migraines: In studies involving patients with chronic migraines, investigators examined outcomes related to this treatment. Researchers evaluated how the treatment influenced patients who experience 15 or more headache days per month.

Tolerability and Associated Symptoms

Research also examined the treatment’s role in a range of secondary symptoms and its general tolerability.

  • Symptom Relief: Research also investigated the drug's role in associated symptoms, such as nausea and light sensitivity. These variables were tracked throughout the trial period, with participants reporting changes in severity.
  • Long-Term Follow-up: Studies in the longer-term follow-up phase examined outcomes after six months of treatment. This phase was designed to monitor tolerability and measure sustained observations beyond the initial 12-week core study period.
  • Time to Observation: Clinical trial data described the time until an observation of change, with some participants noting changes within the first month of treatment. This finding was based on changes in reported migraine days.
  • Specific Patient Populations: Investigators conducted studies to evaluate tolerability in elderly patient populations, and investigators evaluated potential differences in tolerability and side effects compared to younger adults.

Key Studies & References

  1. Reporting Quality and Risk of Bias Analysis of Published RCTs Assessing Anti-CGRP Monoclonal Antibodies in Migraine Prophylaxis: A Systematic Review
  2. Real-World Meta-Analysis Confirms Efficacy and Safety of CGRP Treatment Galcanezumab in Migraine
  3. Atogepant for preventing migraine (Technology appraisal guidance TA973)

Frequently Asked Questions (FAQ)

Common questions about Cypomax (FAQ)


Q: Can Cypomax be used by people who are generally healthy, or only by those with a specific condition?

Official regulatory documents describe Cypomax for use in specific, labeled conditions, such as alleviating allergic symptoms and appetite stimulation. The drug's efficacy has been established for these purposes in patients with these conditions. Regulatory information indicates that its use is established based on a specific clinical need.


Q: Is it true that Cypomax can interact with many over-the-counter supplements?

Regulatory labeling lists specific substance classes that interact, such as those that cause CNS depression. The official documents note that documented interactions with common supplements, food, or herbal products are generally not included in the primary regulatory interaction sections.


Q: What does 'contraindicated' mean in relation to Cypomax use?

The term contraindication is used by regulatory bodies to indicate an absolute prohibition for the use of the drug in a specific patient population or medical circumstance. This restriction is based on the formally documented potential for severe adverse effects or harm in the defined population.


Q: Why do some people need to avoid Cypomax due to liver or kidney issues?

The official safety profile documents serious adverse reactions involving the liver, such as hepatic failure and jaundice. Regulatory guidance states that the drug's elimination is reduced in renal insufficiency, which is a condition requiring close clinical supervision.


Q: Is the purpose of Cypomax purely for relief, or does it address the underlying issue?

Cypomax works by blocking specific receptors in the body, which is a mechanism consistent with alleviating general symptoms. Official descriptions indicate that its function is to modulate signals associated with symptoms, rather than addressing the underlying cause of the condition itself.


Q: What is the general experience of most people who have used Cypomax?

Clinical trial outcomes provide a summary of patient experience based on the drug's efficacy and overall tolerability. Efficacy findings reflect the drug's impact on condition measures, and tolerability data describes the frequency of documented side effects, such as drowsiness.


Q: Do official documents mention anything about weight change associated with Cypomax?

Official product information highlights that Cypomax functions as an appetite stimulant, which is a distinguishing pharmacological effect of the drug. This effect is often linked to subsequent changes in body weight.


Q: Why are certain pre-existing conditions listed as cautions for Cypomax?

These cautions stem from the drug's documented pharmacological effects, such as its anticholinergic activity. This activity requires caution in individuals with conditions like glaucoma or hypertension.


Q: Do studies suggest that Cypomax works better for certain patient groups than others?

Studies have been conducted to evaluate potential differences in the tolerability and side effect profiles of Cypomax in specific patient groups, such as the elderly, compared to younger adults. The regulatory data establishes efficacy based on the overall findings for the labeled population.


Q: Does taking Cypomax at a particular time of day matter?

Administration is typically specified in divided doses taken throughout the day to help maintain a continuous therapeutic effect. The specific timing of those doses may be adjusted due to the drug’s common side effects, such as drowsiness and sedation, which can affect activities that require full attention.


Q: How is Cypomax generally processed by the body?

Official regulatory information defines the drug's journey through the body, which involves its absorption into the bloodstream and its distribution to tissues. The drug is metabolized (broken down) by the body and eventually eliminated (removed) via the urine and feces.


Q: Does Cypomax have a risk of dependence or withdrawal symptoms?

Regulatory documents include statements regarding the drug's potential for abuse or dependence and its status under controlled substance schedules. This information defines the formal legal and clinical classification of the drug concerning addiction risk.


Q: Is an increase in heart rate listed as a possible side effect of Cypomax?

Official adverse reaction documents list tachycardia, or an increase in heart rate, as a possible adverse reaction. This effect is typically associated with the drug's documented anticholinergic activity.


Q: Are there any known interactions between Cypomax and common vitamins?

Official drug documents state that the primary regulatory interaction sections do not include documented interactions with food, specific herbal products, or common vitamins. Interactions that are officially documented primarily involve other medications that affect the central nervous system.


Q: Is Cypomax available generically, or only as a brand name?

The official product label identifies the active ingredient as Cyproheptadine hydrochloride. The drug is commonly available in both its brand-name version, Cypomax, and its generic formulations.


Q: Is it a requirement to have regular lab tests while taking Cypomax?

Due to the documented risk of serious adverse effects involving blood and liver function (e.g., hepatic failure), regulatory guidance includes statements on the need for periodic monitoring or baseline lab work. These tests are intended to check for specific blood and liver markers.


Q: How is Cypomax classified under major government drug schedules?

Official government drug agencies provide the legal status of the drug. This classification determines whether the drug is prescription-only and whether it falls under a specific controlled substance schedule, which defines its regulatory status.

How should Cypomax be stored and disposed of?

How to Store and Dispose of Cypomax?

Cyproheptadine (Cypomax) must be stored at Controlled Room Temperature (20 to 25 C or 68 to 77 F), with permitted excursions up to 30 C (86 F). The product must be protected from excessive heat and freezing; if the liquid product freezes, it should not be used. The medicine must be kept in its well-closed container with a child-resistant closure and stored out of the sight and reach of children.

For disposal, unused or expired medication should be discarded following official guidance. The recommended method is to use a drug take-back program. If a program is unavailable, the medication can be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cypomax found in:

A-Z Index: